PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1550612
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1550612
Primary sclerosing cholangitis Market, By Drug Class (Ursodeoxycholic acid, Corticosteroids, Azathioprine, Mercaptopurine, Budesonide, Obeticholic acid, Monoclonal antibody, Others), By Route of Administration, By Distribution Channel, By Geography
Global primary sclerosing cholangitis market is estimated to be valued at USD 161.2 Mn in 2024 and is expected to reach USD 273.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.8% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 161.2 Mn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 7.80% | 2031 Value Projection: | US$ 273.1 Mn |
Primary sclerosing cholangitis (PSC) is a chronic progressive cholestatic liver disease characterized by multifocal strictures and fibrosis of the intrahepatic and extrahepatic bile ducts. It is associated with inflammatory bowel disease, usually ulcerative colitis, in 70-80% of cases. The exact cause of PSC remains unknown, but it is believed to be an autoimmune disease resulting from a complex interplay between genetic susceptibility and environmental triggers. The global prevalence of PSC is estimated to range between 13-16 cases per 100,000 individuals. Currently, there is no cure for PSC and treatment is focused on relieving symptoms and slowing disease progression. Global primary sclerosing cholangitis market growth is driven by increasing diagnosis rates and rising healthcare expenditure.
Market Dynamics:
Global primary sclerosing cholangitis market growthis driven by factors like rising awareness about the disease, increasing diagnosis rates attributed to advanced diagnostic modalities, and growing geriatric population worldwide who are more susceptible to develop PSC. However, lack of an approved drug for treating PSC and complexities associated with the disease pathogenesis can hamper the market growth. Ongoing R&D for developing novel therapeutics and increasing healthcare expenditures in emerging nations can present high-impact profitable opportunities for market players.
Key Features of the Study:
This report provides in-depth analysis of the global primary sclerosing cholangitis market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global primary sclerosing cholangitis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Intercept Pharmaceuticals, Dr. Falk Pharma GmbH, and Acorda Therapeutics Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global primary sclerosing cholangitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global primary sclerosing cholangitis market
Detailed Segmentation-
- By Drug Class
- Ursodeoxycholic acid (UDCA)
- Corticosteroids
- Azathioprine
- Mercaptopurine
- Budesonide
- Obeticholic acid
- Monoclonal antibody
- Others
- By Route of Administration
- Oral
- Parenteral
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Acorda Therapeutics, Inc.
- Gilead Sciences, Inc.
- NGM Biopharmaceuticals, Inc.
- Intercept Pharmaceuticals, Inc.
- Falk Pharma GmbH
- Allergan Plc.
- Shire Plc.
- Durect Corporation
- Conatus Pharmaceuticals, Inc.
- Sirnaomics, Inc.
- Shenzhen HighTide Biopharmaceutical Ltd.
- Cymabay Therapeutics
- Pliant Therapeutics
- Immunic AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Primary Sclerosing Cholangitis Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global Primary Sclerosing Cholangitis Market, By Drug Class, 2019 - 2031, (USD Mn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Ursodeoxycholic acid (UDCA)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Azathioprine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Mercaptopurine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Budesonide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Obeticholic acid
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Monoclonal antibody
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
6. Global Primary Sclerosing Cholangitis Market, By Route of Administration, 2019 - 2031, (USD Mn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
7. Global Primary Sclerosing Cholangitis Market, By Distribution Channel, 2019 - 2031, (USD Mn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
8. Global Primary Sclerosing Cholangitis Market, By Region, 2019 - 2031, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Acorda Therapeutics, Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Gilead Sciences, Inc.
- NGM Biopharmaceuticals, Inc.
- Intercept Pharmaceuticals, Inc.
- Dr. Falk Pharma GmbH
- Allergan Plc.
- Shire Plc.
- Durect Corporation
- Conatus Pharmaceuticals, Inc.
- Sirnaomics, Inc.
- Shenzhen HighTide Biopharmaceutical Ltd.
- Cymabay Therapeutics
- Pliant Therapeutics
- Immunic AG
- Acorda Therapeutics, Inc.
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About Us and Sales Contact
